Savara Inc (SVRA) - News Archive

Investors Cry Foul: Portnoy Law Firm Leads Class Action Against Savara Inc.In the ever-dynamic world of biopharmaceuticals, another storm is brewing, this time centered around Savara, Inc. (NASDAQ: SVRA), a clinical-sta...

Investors in Savara Inc. (NASDAQ: SVRA) are being alerted to the critical deadline for participation in a class action lawsuit against the company. The Rosen Law Firm and Bragar Eagel & Squire, P.C. have both issued not...

Savara Inc., a biopharmaceutical company specializing in respiratory medicines, is currently navigating a complex landscape of regulatory setbacks and legal entanglements that could profoundly affect its market position...

Rosen Law Firm Leads the Charge in Savara Inc. Class Action as Investors Urged to Secure Representation Before Imminent Deadline NEW YORK, September 20, 2025 - In a significant development for investors in Savara Inc. (...

The biopharmaceutical landscape is experiencing turbulence, as several notable companies face legal challenges that have captured the attention of investors. In recent developments, Bragar Eagel & Squire, P.C., a respec...

In a noteworthy development in the biotech sector, Savara Inc. (NASDAQ: SVRA) faces a substantial class action lawsuit filed on behalf of its investors, pointing to potentially serious implications for the company’s fut...

In a significant development for Savara Inc. (NASDAQ: SVRA), the Pomerantz Law Firm has announced that it is investigating potential claims on behalf of the company s investors. As the biotech sector continues to experi...

Savara Inc. Strengthens Talent Pool with Strategic Inducement Grants In a significant move aimed at bolstering its workforce, Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developin...

Savara Inc. Secures $200 Million Non-Dilutive Financing and Advances Pioneering Treatments for Rare Respiratory Diseases In an impressive maneuver that underscores its commitment to addressing rare respiratory diseases,...

Savara Inc. (Nasdaq: SVRA), a leader in the clinical biopharmaceutical landscape focused on addressing rare respiratory diseases, is making significant strides both in its workforce recruitment and in advancing its clin...

Savara Inc. Advances Toward Regulatory Approval for MOLBREEVI: Pioneering Treatment for Rare Lung Disease In an exciting development for patients with a rare and debilitating lung condition, Savara Inc. a clinical-stage...

Innovations in Breath: Savara s Molgramostim Shows Promise for Autoimmune Pulmonary Alveolar Proteinosis In the world of biopharmaceuticals, incremental steps toward innovation often yield substantial benefits for patie...

Savara s Phase 3 IMPALA-2 Trial on Inhaled Molgramostim: A Promising Step for Autoimmune Pulmonary Alveolar Proteinosis Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focusing on innovative solut...

In recent years, the field of respiratory medicine has witnessed burgeoning interest in innovative therapies for rare diseases. One such condition, autoimmune pulmonary alveolar proteinosis (aPAP), presents significant...

As the medical field continues to evolve, the focus on patient-centered approaches is becoming increasingly crucial, particularly in rare diseases. Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company...

In the realm of rare respiratory diseases, advancements in treatment options can substantially alter the landscape of patient care. Savara Inc. a clinical-stage biopharmaceutical company recognized for its commitment to...

Savara Unveils Promising Data from Phase 3 IMPALA-2 Trial of Molgramostim in aPAP and Announces New Employment Inducement Grant LANGHORNE, Pa. Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company commi...

Savara Inc.: A New Wave of Innovation and GrowthIn the constantly evolving field of biopharmaceuticals, Savara Inc. stands out as a dynamic player. Based in Langhorne, Pennsylvania, and listed on Nasdaq under the ticker...

: This article discusses Savara Inc. s recent announcement regarding an employment inducement grant, highlighting the company s strategic moves in the pharmaceutical landscape. Given its current share price of $4.42, th...

In the year of our Lord 2024, it is with great anticipation that Savara Inc., a clinical-stage biopharmaceutical company dedicated to the advancement of therapies for rare respiratory afflictions, has publicly announced...